Remedium Lifecare Ltd

Remedium Lifecare's latest Q2 FY26 results show a net profit increase of 85.38% to ₹8.62 crores, but a 2.04% decline in net sales raises concerns about sustainability, especially given significant year-on-year declines in both sales and profit. Overall, while there are some positive signs, the company's financial health remains precarious.

Remedium Life reported an operating income of 405.25 Cr and a slight operating loss of 1.09 Cr for the year ending March 2025, resulting in a profit after tax of 2.13 Cr and an EPS of 0.04. Despite total liabilities and assets both at 1,720.31 Cr, the company faced significant negative cash flow from operations at -1,134.00 Cr, offset by a positive cash flow from financing activities.

As of 04-Nov, Remedium Lifecare Ltd's stock price is 1.59, up 6.0% today and outperforming its sector. Despite a recent short-term recovery, the stock has declined significantly year-to-date and over the past year, while the broader market is experiencing downward pressure.

As of 24-Sep, Remedium Lifecare Ltd's stock price is at 1.50, with no change. Despite recent short-term gains, the company faces significant financial challenges, including high debt, consecutive quarterly losses, and a year-to-date decline of -58.03%, indicating a bleak long-term outlook.

As of 23-Sep, Remedium Lifecare Ltd's stock price is at 1.50, down 3.23%, with a year-to-date decline of 58.03%. The stock has underperformed its sector and the broader market, indicating weak investor participation and mixed momentum.

As of 22-Sep, Remedium Lifecare Ltd's stock price is 1.55, up 1.97% recently, but it faces significant challenges with a high Debt to EBITDA ratio and a history of losses. While it has outperformed the Sensex in the short term, it has a year-to-date decline of -56.63%, indicating substantial long-term risks.

As of 19-Sep, Remedium Lifecare Ltd's stock price is 1.52, up 1.33% today, but it has declined 76.31% over the past year, indicating significant long-term challenges despite a recent short-term gain of 16.03%. The company faces high debt levels and declining sales, raising concerns about its financial health and investor interest.

As of 18-Sep, Remedium Lifecare Ltd is priced at 1.50, with no change and a significant decline of -76.44% over the past year, indicating ongoing financial struggles despite a slight increase in delivery volume. The company's poor performance relative to the market and negative financial metrics suggest a challenging outlook for investors.

As of 17-Sep, Remedium Lifecare Ltd's stock price is 1.50, down 0.66%. The stock has significantly underperformed the market, with a year-to-date decline of 58.03% and negative financial results contributing to poor investor sentiment.

As of 15-Sep, Remedium Lifecare Ltd's stock price is at 1.52, unchanged, with short-term gains of 5.56% over the past week but a significant year-to-date decline of 57.47%. The company faces serious financial challenges, including a high Debt to EBITDA ratio and a drastic decline in net sales, raising concerns about its long-term viability.

As of 12-Sep, Remedium Lifecare Ltd's stock price is at 1.52, unchanged, but has outperformed its sector today. Despite recent short-term gains, the company's significant losses and poor financial health indicate a bleak long-term outlook.

As of 11-Sep, Remedium Lifecare Ltd's stock price is at 1.52, up 2.7%, but faces significant challenges with a high Debt to EBITDA ratio and a 76.36% decline in net sales, indicating poor long-term growth potential. Despite recent short-term gains, the stock has underperformed over the past year, highlighting volatility and financial risks.

As of 10-Sep, Remedium Lifecare Ltd's stock price is 1.48, up 2.78%, with strong short-term performance but significant long-term challenges, including a 58.59% year-to-date decline and poor financial health indicators. Despite recent gains, the company's sustainability and recovery prospects appear risky.

As of 09-Sep, Remedium Lifecare Ltd's stock price is at 1.44, unchanged, with recent short-term gains but significant long-term declines of -59.71% year-to-date and -79.43% over the past year, alongside poor financial performance and declining investor confidence.

As of 08-Sep, Remedium Lifecare Ltd's stock price is at 1.44, with a recent short-term gain of 3.60%. However, the company faces significant challenges, including a high Debt to EBITDA ratio and negative performance over the last year, indicating a risky investment despite short-term improvements.

As of 05-Sep, Remedium Lifecare Ltd's stock price is 1.44, up 9.09% recently, but faces significant challenges with a high Debt to EBITDA ratio and declining net sales, leading to a poor long-term growth outlook. Despite short-term gains, the stock has underperformed over the past year, indicating volatility and financial risks.

As of 04-Sep, Remedium Lifecare Ltd's stock price is at 1.32, up 3.13% today, but the company faces significant financial challenges, including high debt levels and consecutive quarterly losses, leading to a negative long-term outlook despite recent short-term gains.

As of 03-Sep, Remedium Lifecare Ltd's stock price is 1.28, down 3.03%, with a year-to-date decline of 64.19% and an 81.12% drop over the past year. The company faces negative financial results, high debt, and a poor growth outlook, contributing to its significant underperformance compared to the market.